eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2018
vol. 69
 
Share:
Share:
abstract:
Original paper

EGOT lncRNA in head and neck squamous cell carcinomas

Tomasz Kolenda
,
Magdalena Kopczyńska
,
Kacper Guglas
,
Anna Teresiak
,
Renata Bliźniak
,
Izabela Łasińska
,
Jacek Mackiewicz
,
Katarzyna Lamperska

Pol J Pathol 2018; 69 (4): 356-365
Online publish date: 2019/01/31
View full text Get citation
 
PlumX metrics:
Head and neck squamous cell carcinomas (HNSCCs) are one of the most challenging cancers to cure. In this study, we focused on eosinophil granule ontogeny transcript (EGOT), a transcriptional regulator of granule protein expression during eosinophil development that has been previously associated with cancers.

Expression levels of EGOT and other selected genes as well as clinical pathology data from HNSCC samples, were obtained from The Cancer Genome Atlas (TCGA) and analysed using GraphPad Prism 5. Our results indicated that the expression of EGOT is slightly down-regulated in HNSCC, depending on tumour grade and location, and is only up-regulated in grade 4 tumours and those located in the pharynx. EGOT expression levels were found to vary according to age, N-stage, grade, lymph node dissection and human papillomavirus (HPV) infection.

Patients with higher levels of EGOT expression have longer disease-free survival and overall survival outcomes. Further analysis revealed that EGOT targets are associated with cell division, proliferation, protein modification, drug response and cell motility. Taken together, our findings suggest that the EGOT

is involved in the progression of HSNCC and seems particularly associated with virus-related forms of HNSCC.
keywords:

eosinophil granule ontogeny transcript, lncRNA, head and neck cancers, biomarker

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.